Testing a new radioactive treatment for advanced neuroendocrine tumors

Plain-English translation of NCT06784752 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called [177Lu]Lu-DOTA-TATE, a radioactive treatment that targets neuroendocrine tumors (rare cancers that start in hormone-producing cells). Researchers want to see if this medication, given together with a standard hormone medicine called , works better than alone for people with advanced disease that has spread or cannot be removed by surgery. The study will compare two groups: one receiving the new radioactive treatment plus , and another receiving only.

Currently, people with advanced neuroendocrine tumors have limited treatment options early on. This trial exists to find out whether this new radioactive medication can help control the disease better and improve outcomes for newly diagnosed patients, especially those with significant tumor burden.

Do you qualify?

You likely qualify if…

you have been diagnosed with an advanced neuroendocrine tumor (a rare, slow-growing cancer) within the past 6 months
your tumor has spread to other parts of your body or cannot be surgically removed
your tumor shows high disease burden, such as tumors larger than 4 cm, multiple tumors, elevated liver markers, bone involvement, or symptoms like pain or weight loss
your tumor cells have a specific receptor (called SSTR) that can be detected on imaging scans
you are at least 12 years old and in generally good health (ECOG performance status 0–1)

You likely don't qualify if…

you have previously received radioactive cancer treatment for neuroendocrine tumors
you have been treated with interferons, mTOR inhibitors, chemotherapy, or other systemic therapies (other than somatostatin analogues) for this cancer
you have already received more than 4 cycles of octreotide LAR or similar somatostatin analogue therapy
you have severely low blood cell counts or significantly impaired kidney or liver function

What participation looks like

You will participate in a screening phase to confirm you qualify, followed by a treatment phase where you will be randomly assigned to receive either the new radioactive medication plus injections, or injections alone. You will have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and to watch for any side effects. After treatment ends, you will have a follow-up phase with continued monitoring to assess long-term outcomes.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(65 sites)

United States

Mayo Clinic Arizona, Scottsdale, Arizona

Highlands Oncology Group, Fayetteville, Arkansas

Rocky Mountain Cancer Centers, Denver, Colorado

Hartford Hospital, Hartford, Connecticut

Yale New Haven Hospital, New Haven, Connecticut